Heterocyclic Compounds, 3-Ring
"Heterocyclic Compounds, 3-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic
Concept/Terms
Heterocyclic Compounds, 3-Ring- Heterocyclic Compounds, 3-Ring
- 3-Ring Heterocyclic Compounds
- Compounds, 3-Ring Heterocyclic
- Heterocyclic Compounds, 3 Ring
- Heterocyclic Cpds, 3 Ring
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 3-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 3-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 3-Ring" by people in Harvard Catalyst Profiles by year, and whether "Heterocyclic Compounds, 3-Ring" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 2 | 4 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 3 | 4 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 4 | 8 |
| 2018 | 12 | 3 | 15 |
| 2019 | 7 | 6 | 13 |
| 2020 | 8 | 2 | 10 |
| 2021 | 5 | 8 | 13 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 4 | 4 |
Below are the most recent publications written about "Heterocyclic Compounds, 3-Ring" by people in Profiles.
-
Metabolic implications and safety of dolutegravir use in pregnancy. Lancet HIV. 2023 09; 10(9):e606-e616.
-
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Upadacitinib as a Novel Treatment in Therapy Refractory Collagenous Colitis. Inflamm Bowel Dis. 2023 08 01; 29(8):1352-1353.
-
Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis. 2023 07 05; 29(7):1175-1176.
-
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort. Clin Infect Dis. 2022 09 10; 75(4):715-718.
-
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med. 2022 09 01; 387(9):799-809.
-
Upadacitinib for ulcerative colitis. Lancet. 2022 06 04; 399(10341):2077-2078.
-
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV. 2022 05; 9(5):e332-e340.
-
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. J Acquir Immune Defic Syndr. 2022 05 01; 90(1):27-32.
-
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. AIDS. 2022 09 01; 36(11):1511-1520.